Company News
-
Nov 4, 2021Clover Biopharmaceuticals Announces Offer Price and Allotment Results of the Global Offering
-
Sep 22, 2021Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
-
Sep 10, 2021Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine
-
Jul 6, 2021Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate
-
Jun 30, 2021Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover's COVID-19 Vaccine for the COVAX Facility
-
Jun 30, 2021Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate
-
May 18, 2021Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
-
Mar 24, 2021Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate
-
Feb 23, 2021Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing
-
Feb 1, 2021Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
-
Feb 1, 2021Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
-
Dec 4, 2020Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates
-
Nov 3, 2020CEPI extends partnership with Clover Biopharmaceuticals to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure
-
Sep 25, 2020Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program
-
Sep 25, 2020Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate
-
Jul 8, 2020CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate
-
Jun 19, 2020Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate
-
Jun 8, 2020GL Ventures Completes $24 Million Series B-2 Investment in Clover Biopharmaceuticals
-
Apr 27, 2020CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals' Australian Subsidiary
-
Mar 24, 2020Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
